ReviewMarine drugs2022
Fungal Bergamotane Sesquiterpenoids-Potential Metabolites: Sources, Bioactivities, and Biosynthesis.
Review in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Rosanoid diterpenoids: structural diversity, classification and biological activities.ADMET & DMPK · 2026Review
- Unlocking the Potential of Thermal Post-Treatments: A Study on Odor Emission Control inMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The marine environment represents the largest ecosystem on the Earth's surface. Marine-derived fungi are of remarkable importance as they are a promising pool of diverse classes of bioactive metabolites. Bergamotane sesquiterpenoids are an uncommon class of terpenoids. They possess diverse biological properties, such as plant growth regulation, phototoxic, antimicrobial, anti-HIV, cytotoxic, pancreatic lipase inhibition, antidiabetic, anti-inflammatory, and immunosuppressive traits. The current work compiles the reported bergamotane sesquiterpenoids from fungal sources in the period ranging from 1958 to June 2022. A total of 97 compounds from various fungal species were included. Among these metabolites, 38 compounds were derived from fungi isolated from different marine sources. Furthermore, the biological activities, structural characterization, and biosynthesis of the compounds are also discussed. The summary in this work provides a detailed overview of the reported knowledge of fungal bergamotane sesquiterpenoids. Moreover, this in-depth and complete review could provide new insights for developing and discovering new valuable pharmaceutical agents from these natural metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.